Details for New Drug Application (NDA): 220172
✉ Email this page to a colleague
NDA 220172 describes ASCORBIC ACID, which is a drug marketed by Fresenius Kabi Usa and Stira and is included in two NDAs. It is available from two suppliers. Additional details are available on the ASCORBIC ACID profile page.
The generic ingredient in ASCORBIC ACID is ascorbic acid. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the ascorbic acid profile page.
The generic ingredient in ASCORBIC ACID is ascorbic acid. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the ascorbic acid profile page.
Summary for 220172
| Tradename: | ASCORBIC ACID |
| Applicant: | Stira |
| Ingredient: | ascorbic acid |
| Patents: | 0 |
Suppliers and Packaging for NDA: 220172
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ASCORBIC ACID | ascorbic acid | SOLUTION;INTRAVENOUS | 220172 | ANDA | Renova Pharmaceuticals LLC | 84897-058 | 84897-058-01 | 1 VIAL, GLASS in 1 CARTON (84897-058-01) / 50 mL in 1 VIAL, GLASS |
| ASCORBIC ACID | ascorbic acid | SOLUTION;INTRAVENOUS | 220172 | ANDA | Renova Pharmaceuticals LLC | 84897-058 | 84897-058-25 | 25 VIAL, GLASS in 1 TRAY (84897-058-25) / 50 mL in 1 VIAL, GLASS |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 25,000MG/50ML (500MG/ML) | ||||
| Approval Date: | Jul 30, 2026 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
